Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries

References

• Hagist C, Kotlikoff LJ. Who's Going Broke? Comparing Growth in Health care Costs in Ten OECD Countries, NBER Working Papers, No. 11833, December 2005
   Google Scholar
• Cox P, ed. Financing Sustainable Healthcare In Europe: New Approaches For New Outcomes, February 2007. Available at: http://www.sustainhealthcare.org/navigation/The_Cox_Report.pdf. Accessed December 12, 2008
   Google Scholar
• The Conference Board of Canada. Challenging Health Care System Sustainability: Understanding Health System Performance of Leading Countries. March 2004. Available at: http://www.conferenceboard.ca.
   Google Scholar
• International Trade Administration. Pharmaceutical Price Controls in OECD Countries Implications for U.S. Consumers, Pricing, Research and Development, and Innovation. Washington, DC: US Department of Commerce, December 2004
   Google Scholar
• Tyrer JH, Eadie MJ, Sutherland JM, et al. Outbreak of anticonvulsant intoxication in an Australian city. BMJ 1970;4:271-3
   PubMed Web of Science ®Google Scholar
• Dahl M, Wolf P. Comparative daily profiles of lamotrigine. Poster #3.019 presented at the 1 st Annual North American Regional Epilepsy Congress of the American Epilepsy Society, December 2006, San Diego, CA
   Google Scholar
• Cremieux PY, Ouellette P, Petit P. Do drugs reduce utilization of other healthcare resources? Pharmacoeconomics. 2007;25:209-21
   Google Scholar
• LeLorier J, Duh MS, Paradis PE, et al. Economic impact of generic substitution of lamotrigine: projected costs in the United States using findings in a Canadian setting. Curr Med Res Opin 2008;24:1069-81
   PubMed Web of Science ®Google Scholar
• Andermann F, Duh MS, Gosselin A, et al. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;48:464-9
   PubMed Web of Science ®Google Scholar
• Labiner DM, Duh MS, Paradis PE, et al. Impact of generic substitution of antiepileptic drugs on medical resource utilization in the United States. Poster presented at the 62 nd Annual Meeting of American Epilepsy Society, Seattle, WA, December 5-9, 2008
   Google Scholar
• Volger S, Habl C, Leopold C, et al. PPRI Report. Commissioned by European Commission, Directorate-General Health and Consumer Protection and Austrian Federal Ministry of Health, Family and Youth, June 2008. Available at: http://ppri.oebig.at/Downloads/Publications/PPRI_Report_final.pdf. Accessed on January 16, 2009
   Google Scholar
• Crawford P, Feely M, Guberman A, et al. Are there potential problems with generic substitution of antiepileptic drugs? A review of issues. Seizure 2006;15:165-76
   PubMed Web of Science ®Google Scholar
• Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy Behav 2004;5:995-8
   PubMed Web of Science ®Google Scholar
• Haskins L, Tomaszewki KJ, Crawford P. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy. Epilepsy Behav 1998;11:98-105
   Google Scholar
• Caves RE, Whinston MD, Hurwitz MA. Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Papers: Microeconomics. Washington, DC: Brookings Institution, 1991, 48p
   Google Scholar
• Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;54:752-73
   PubMed Web of Science ®Google Scholar
• Association Québécoise des Établissements de Santé et de Services Sociaux (AQESSS), Système intégré d’analyse de la performance (SIAP). Montréal, Québec: AQESSS, 2004-5
   Google Scholar
• Statistics Canada, CANSIM Table 320-0020, series v41691872 and v41691869
   Google Scholar
• Mooney CZ, Duval RD. Bootstrapping: a nonparametric approach to statistical inference. Newbury Park, CA: Sage Publications, 1993
   Google Scholar
• Organization for Economic Co-operation and Development (OECD), OECD Health Data 2008, June 8 th edition. Available at: http://www.oecd.org.
   Google Scholar
• IMS Health, units and sales. France, Germany, Italy and United Kingdom. Risperidone, gabapentin, lamotrigine, and oxcarbazepine. January 2001 to July 2008. Available at: http://www.imshealth.com.
   Google Scholar
• Kaiser Family Foundation. Prescriptions drug trends, Fact Sheets #3057-03 to 3057-07, November 2005, June 2006, and May 2007. Available at: http://www.kff.org. Accessed August 7, 2008
   Google Scholar
• Bank of Canada. Monthly and Annual Noon Exchange Rates Averages, Average of 251 days, 2007. http://www.bank-banque-canada.ca/en/rates/exchange_avg_pdf.html. Accessed August 8, 2008
   Google Scholar
• Eurostat. ECU/EUR exchange rates versus national currencies, 2007 http://epp.eurostat.ec.europa.eu. Accessed August 8, 2008
   Google Scholar
• LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008;70:2179-86
   PubMed Web of Science ®Google Scholar
• Grootendorst, P. Do drugs matter? Effect of drug plan eligibility on drug use among the elderly, social assistance recipient and the general population. Hamilton, Ontario: Research Institute for Quantitative Studyies in Economics and Population (QSEP), 2000:77p
   Google Scholar
• Blachier C, Kanavos P. Pharmaceutical Pricing and Reimbursement. Available at http://ec.europa.eu/enterprise/phabiocom/docs/tse/france.pdf
   Google Scholar
• Brandt N. Moving towards more sustainable healthcare financing in Germany. OECD Economics Department, Working Paper No. 612, 2008
   Google Scholar
• Garattini L, Ghislandi S. Off-patent drugs in Italy. A short-sighted view? Eur J Health Econ 2006;7:79-83
   PubMedGoogle Scholar
• Nguyen-Kim L, Or Z, Paris V, et al. The politics of drug reimbursement in England, France and Germany. Health Econ Letter. No. 99, October 2005
   Google Scholar
• Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996;23:139-48
   PubMed Web of Science ®Google Scholar
• Grimes DA, Schultz KF. Bias and causal associations in observational research. Lancet 2002;359:248-52
   PubMed Web of Science ®Google Scholar